In today's increasingly competitive market, efficient response and exceptional cost-performance have become crucial for ...

Health Canada begins a priority review of semaglutide 2.4 mg, a weekly treatment by Novo Nordisk for MASH, a liver disease ...

Novo Nordisk's collaboration with telehealth providers offers semaglutide at $499/month, enhancing access for self-paying ...

Of the total ER visits, nearly 70% involved GI issues, 15% of which led to hospitalization, according to a new study.

Effective July 1, 2025, CVS Caremark will place Wegovy injection 2.4 mg as preferred on its commercial template formularies.

Novo Nordisk has teamed up with Hims & Hers Health, LifeMD and Ro for cash-paying patients to access Wegovy injection 2.4 mg ...

Just today, this drug became more widely available. Some product is now facing a recall following an apparent storage error.

PLAINSBORO, N.J., April 29, 2025 /PRNewswire/ -- Today, Novo Nordisk announced it is expanding patient access to Wegovy ® (semaglutide) injection ... loss in its premium pen delivery device ...

Seizures of potentially dangerous weight loss drugs being sold on the black market in Scotland have soared as online dealers ...

Discover the details about Wegovy, a popular weight loss drug now available for telehealth purchase. Understand its benefits, ...